Amazon.com Inc vs Mesoblast Limited — how do they compare? Amazon.com Inc trades at $268.84 (market cap $2.94T), while Mesoblast Limited trades at $16.76 (market cap $2.21B). The key difference: Amazon.com Inc is far larger — about 1330.3× Mesoblast Limited's market cap, and Amazon.com Inc is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.
| AMZN | MESO | |
|---|---|---|
Market Cap | $2.94T | $2.21B |
Volume | 3,931,282 | — |
Sector | Consumer Cyclical | Technology |
52-Week High | $284.02 | $20.96 |
52-Week Low | $198.79 | $12.88 |
Enterprise Value | $3.04T | $2.21B |
Signals from Pluang's Aura AI — not financial advice
Amazon (AMZN) trades at $268.92, down 3.3% over the past 24 hours, but maintains strong fundamental momentum with revenue growing to $716.92 billion in 2025 and net income reaching $77.67 billion. The stock shows a bullish technical setup with moving averages supporting upward momentum, while analyst sentiment remains overwhelmingly positive with 89% buy ratings and a $333.86 consensus price target representing 24% upside potential.
Amazon's outlook remains favorable with accelerating AI-driven growth in AWS and expanding profit margins, though investors face risks from intense retail competition and substantial capital expenditures. The company's dominant market position and strong cash flow generation support continued expansion, but execution on massive infrastructure investments will be critical for sustained shareholder returns.
MESO trades at $16.82, up 0.84% with bullish technical signals from moving averages. The company shows strong revenue growth with Ryoncil generating $115M in its first year, but remains unprofitable with a -144.33% net income margin. Recent developments include positive Phase 3 trial progress and BLA filing for heart failure treatment, supported by analyst consensus leaning bullish with 45% buy ratings.
MESO presents a high-risk, high-reward opportunity with promising commercial traction offset by significant losses. Investment thesis hinges on successful pipeline development and profitability turnaround, while risks include clinical trial outcomes, regulatory approvals, and sustained cash burn requiring careful monitoring of execution milestones.
Trailing returns across standard periods
Latest headlines on both assets
Amazon.com, Inc. is an online retailer that offers a wide range of products. The Company products include books, music, computers, electronics and numerous other products. Amazon offers personalized shopping services, Web-based credit card payment, and direct shipping to customers. Amazon also operates a cloud platform offering services globally.
Read more on AMZN →Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →